DermTech Common Stock Total Equity vs Other Current Liab Analysis
DMTK Stock | USD 0.35 0.04 10.26% |
DermTech financial indicator trend analysis is much more than just examining DermTech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DermTech is a good investment. Please check the relationship between DermTech Common Stock Total Equity and its Other Current Liab accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.
Common Stock Total Equity vs Other Current Liab
Common Stock Total Equity vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DermTech Common Stock Total Equity account and Other Current Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between DermTech's Common Stock Total Equity and Other Current Liab is -0.19. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of DermTech, assuming nothing else is changed. The correlation between historical values of DermTech's Common Stock Total Equity and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of DermTech are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Common Stock Total Equity i.e., DermTech's Common Stock Total Equity and Other Current Liab go up and down completely randomly.
Correlation Coefficient | -0.19 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Other Current Liab
Most indicators from DermTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DermTech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.Selling General Administrative is expected to rise to about 46 M this year, although the value of Issuance Of Capital Stock will most likely fall to about 5 M.
DermTech fundamental ratios Correlations
Click cells to compare fundamentals
DermTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DermTech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 18.2M | 69.8M | 248.3M | 202.1M | 121.9M | 82.3M | |
Other Current Liab | 2.7M | 2.8M | 6.3M | 11.4M | 8.7M | 9.1M | |
Total Current Liabilities | 5.7M | 5.4M | 12.2M | 15.6M | 13.4M | 14.1M | |
Total Stockholder Equity | 12.5M | 63.5M | 229.7M | 132.4M | 57.2M | 64.2M | |
Net Tangible Assets | 12.5M | 63.5M | 229.7M | 132.4M | 152.2M | 159.8M | |
Retained Earnings | (91.1M) | (126.4M) | (206.4M) | (323.0M) | (423.9M) | (402.7M) | |
Accounts Payable | 1.6M | 1.6M | 2.9M | 2.4M | 1.5M | 1.2M | |
Cash | 15.4M | 24.2M | 176.9M | 77.8M | 36.7M | 33.4M | |
Non Current Assets Total | 1.1M | 2.9M | 15.5M | 66.0M | 60.2M | 30.5M | |
Non Currrent Assets Other | 12.4M | 84K | 167K | 168K | 3.5M | 3.3M | |
Other Assets | 84K | 167K | 3.2M | 3.7M | 4.2M | 4.4M | |
Cash And Short Term Investments | 15.4M | 63.8M | 225.3M | 126.2M | 55.9M | 48.7M | |
Common Stock Total Equity | 4.1M | 1K | 2K | 3K | 2.7K | 2.6K | |
Common Stock Shares Outstanding | 7.0M | 17.0M | 28.9M | 30.0M | 32.6M | 34.3M | |
Short Term Investments | 12.4M | 39.5M | 48.4M | 48.4M | 19.1M | 18.2M | |
Liabilities And Stockholders Equity | 18.2M | 69.8M | 248.3M | 202.1M | 121.9M | 82.0M | |
Capital Surpluse | 103.6M | 189.8M | 436.2M | 456.2M | 524.6M | 550.8M | |
Inventory | 35K | 104K | 480K | 1.8M | 1.0M | 1.1M | |
Other Current Assets | 1.1M | 1.5M | 3.2M | 3.9M | 2.3M | 1.3M | |
Other Stockholder Equity | 103.6M | 120.1M | 436.2M | 456.2M | 480.9M | 505.0M | |
Total Liab | 5.7M | 6.3M | 18.6M | 69.7M | 64.8M | 68.0M | |
Property Plant And Equipment Gross | 977K | 2.7M | 12.3M | 6.4M | 60.5M | 63.5M | |
Total Current Assets | 17.2M | 66.9M | 232.8M | 136.0M | 61.8M | 51.8M | |
Accumulated Other Comprehensive Income | (239K) | (1K) | (124K) | (774K) | 178K | 186.9K | |
Common Stock | 4.1M | 1K | 2K | 3K | 2.7K | 2.6K | |
Property Plant Equipment | 977K | 2.7M | 12.3M | 6.4M | 7.3M | 7.7M | |
Net Debt | (15.4M) | (23.9M) | (169.0M) | (21.9M) | 17.7M | 18.5M | |
Net Invested Capital | 12.5M | 63.5M | 229.7M | 132.4M | 57.2M | 101.0M | |
Net Working Capital | 11.4M | 61.5M | 220.6M | 120.4M | 48.3M | 72.5M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as DermTech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for DermTech Stock analysis
When running DermTech's price analysis, check to measure DermTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DermTech is operating at the current time. Most of DermTech's value examination focuses on studying past and present price action to predict the probability of DermTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DermTech's price. Additionally, you may evaluate how the addition of DermTech to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is DermTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DermTech. If investors know DermTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DermTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.65) | Revenue Per Share 0.465 | Quarterly Revenue Growth 0.106 | Return On Assets (0.39) | Return On Equity (1.22) |
The market value of DermTech is measured differently than its book value, which is the value of DermTech that is recorded on the company's balance sheet. Investors also form their own opinion of DermTech's value that differs from its market value or its book value, called intrinsic value, which is DermTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DermTech's market value can be influenced by many factors that don't directly affect DermTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DermTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DermTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DermTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.